Issues related to health care, the Food and Drug Administration (FDA), Rx-to-OTC switch issues, influenza, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, TRICARE Pharmacy Program, VICP Program, and insulin price cap; Type One Diabetes and military healthcare; Educational discussions around Vaccine Injury Compensation Program;
H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169) implementation;
Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorization;
H.R.830, HELP Copays Act; S.127, Pharmacy Benefit Manager Transparency Act of 2023; H.R.3285, Fairness for Patient Medications Act; S.1339, Pharmacy Benefit Manager Reform Act; H.R.5378, Lower Costs, More Transparency Act; S.3430, Better Mental Health Care Lower-Cost Drugs and Health Extenders Act; S.2973, Modernizing and Ensuring PBM Accountability Act; H.R.6283, DRUG Act.
Issues related to related to appropriations, federal health programs, and prescription drugs; FY2024 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, S.2624/H.R.5894; H.R.3746, Fiscal Responsibility Act of 2023 (P.L.118-5) implementation; H.R.2882, Further Consolidated Appropriations Act, 2024, P.L.118-47; FY2025 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations process.
General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; Drug Pricing; H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169) implementation; CMMI Proposed Accelerated Approval Payment Policy; CMMI Medicaid Proposed Rebate Rule.
Biopharmaceutical innovation and patent policy issues.
Bayh-Dole march-in rights policy issues.
Issues related to pharmaceutical IP and supply chain.
Tax issues related to implementation of H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169).
Issues related to R&D tax credit; H.R.7024, Tax Relief for American Families and Workers Act of 2024.
Duration: February 1, 2018
to
present
General Issues: Health Issues , Budget/Appropriations , Medicare/Medicaid , Copyright/Patent/Trademark , Trade (Domestic & Foreign) , Taxation/Internal Revenue Code
Spending: about $1,200,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2018: U.S. Senate, House of Representatives, Executive Office of the President (EOP)
Related Foreign Entities:
Sanofi SA (75008 Paris, FRA); contribution to lobbying: $0; ownership 100%
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
Jason Van Pelt Legislative Director, Senior LA, LA, Staff Asst: Cong. Ed Whitfield
Shay Hancock MLA Sen. Murray (D-WA), LA Rep Smith (D-WA)
Katherine Dapper Staff Asst. Sen. Murray (D-WA)
Hunter Moorhead Adv,Cochran;NatlEcoCoun;SenAppro;LACochran;HRAg;LAParker
Jason Gleason Chief of Staff/Legislative Director, Rep. John Sarbanes; Legislative Director/Legislative Asst/Legislative Correspondent/Staff Asst, Sen. Paul Sarbanes
Brittany Hernandez Senior Legislative Assistant, Legislative Assistant, Legislative Correspondent, Staff Assistant: Rep. Steve Cohen
Ivelisse Porroa-Garcia Policy Director, Congressional Hispanic Caucus (CHC); Legislative Assistant, Rep. Raul Ruiz; Staff Assistant, Sen. Barbara Boxer
Cheryl Jaeger Shared employee, Ofc of the Speaker & Ofc of VA 07; Sr Policy Adv, Maj Leader, Rep. Cantor; Sr Policy Adv, Republican Whip, Rep. Cantor; Sr Policy Adv, Majority Whip, Rep. Blunt; Prof Staff House Committee on E & C; Sr LA to Rep. Cox
Mathew Lapinski n/a
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
1st Quarter, 2024
In Q1, Crossroads Strategies, LLC lobbied for Sanofi US Services Inc. , earning $50,000. The report was filed on April 22.
Original Filing: 301573152.xml
Lobbying Issues
Issues related to health care, the Food and Drug Administration (FDA), Rx-to-OTC switch issues, influenza, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, TRICARE Pharmacy Program, VICP Program, and insulin price cap; Type One Diabetes and military healthcare; Educational discussions around Vaccine Injury Compensation Program;
H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169) implementation;
Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorization;
H.R.830, HELP Copays Act; S.127, Pharmacy Benefit Manager Transparency Act of 2023; H.R.3285, Fairness for Patient Medications Act; S.1339, Pharmacy Benefit Manager Reform Act; H.R.5378, Lower Costs, More Transparency Act; S.3430, Better Mental Health Care Lower-Cost Drugs and Health Extenders Act; S.2973, Modernizing and Ensuring PBM Accountability Act; H.R.6283, DRUG Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to related to appropriations, federal health programs, and prescription drugs; FY2024 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, S.2624/H.R.5894; H.R.3746, Fiscal Responsibility Act of 2023 (P.L.118-5) implementation; H.R.2882, Further Consolidated Appropriations Act, 2024, P.L.118-47; FY2025 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations process.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; Drug Pricing; H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169) implementation; CMMI Proposed Accelerated Approval Payment Policy; CMMI Medicaid Proposed Rebate Rule.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Biopharmaceutical innovation and patent policy issues.
Bayh-Dole march-in rights policy issues.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to pharmaceutical IP and supply chain.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Tax issues related to implementation of H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169).
Issues related to R&D tax credit; H.R.7024, Tax Relief for American Families and Workers Act of 2024.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2023
In Q4, Crossroads Strategies, LLC lobbied for Sanofi US Services Inc. , earning $50,000. The report was filed on Jan. 20.
Original Filing: 301533762.xml
Lobbying Issues
Issues related to health care, the Food and Drug Administration (FDA), Rx-to-OTC switch issues, influenza, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, TRICARE Pharmacy Program, VICP Program, and insulin price cap; Educational discussions around Vaccine Injury Compensation Program;
H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169) implementation;
Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorization;
H.R.830, HELP Copays Act; S.127, Pharmacy Benefit Manager Transparency Act of 2023; H.R.3285, Fairness for Patient Medications Act; S.1339, Pharmacy Benefit Manager Reform Act; H.R.5378, Lower Costs, More Transparency Act; S.3430, Better Mental Health Care Lower-Cost Drugs and Health Extenders Act; S.2973, Modernizing and Ensuring PBM Accountability Act; H.R.6283, DRUG Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to related to appropriations, federal health programs, and prescription drugs; FY2024 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, S.2624/H.R.5894; H.R.3746, Fiscal Responsibility Act of 2023 (P.L.118-5) implementation; H.R.2811, Limit, Save, Grow Act of 2023.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; Drug Pricing;
H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169) implementation;
CMMI Proposed Accelerated Approval Payment Policy;
Medicaid Proposed Rebate Rule.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Biopharmaceutical innovation and patent policy issues.
Trademark legislative proposals.
Bayh-Dole march-in rights policy issues.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to pharmaceutical IP and supply chain.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Tax issues related to implementation of H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169).
Issues related to R&D tax credit; H.R.3938, Build It in America Act.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2023
In Q3, Crossroads Strategies, LLC lobbied for Sanofi US Services Inc. , earning $50,000. The report was filed on Oct. 20, 2023.
Original Filing: 301514333.xml
Lobbying Issues
Issues related to health care, the Food and Drug Administration (FDA), Rx-to-OTC switch issues, influenza, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, TRICARE Pharmacy Program, VICP Program, and insulin price cap;
H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169) implementation;
Pandemic and All-Hazards Preparedness Reauthorization Act (PAHPRA);
H.R.830, HELP Copays Act; S.127, Pharmacy Benefit Manager Transparency Act of 2023; H.R.3285, Fairness for Patient Medications Act; S.1339, Pharmacy Benefit Manager Reform Act;
Educational discussions around Vaccine Injury Compensation Program;
H.R.5378, Lower Costs, More Transparency Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to related to appropriations, federal health programs, and prescription drugs; FY2024 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, S.2624; H.R.3746, Fiscal Responsibility Act of 2023; H.R.2811, Limit, Save, Grow Act of 2023.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; Drug Pricing;
H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169) implementation;
CMMI Proposed Accelerated Approval Payment Policy;
Medicaid Proposed Rebate Rule.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Biopharmaceutical innovation and patent policy issues.
Trademark legislative proposals.
Bayh-Dole march-in rights policy issues.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to pharmaceutical IP and supply chain.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Tax issues related to implementation of H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169).
Issues related to R&D tax credit; H.R.3938, Build It in America Act.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2023
In Q2, Crossroads Strategies, LLC lobbied for Sanofi US Services Inc. , earning $50,000. The report was filed on July 19, 2023.
Original Filing: 301484444.xml
Lobbying Issues
Issues related to health care, the Food and Drug Administration (FDA), Rx-to-OTC switch issues, influenza, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, TRICARE Pharmacy Program, VICP Program, and insulin price cap;
H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169) implementation;
Pandemic and All-Hazards Preparedness Reauthorization Act (PAHPRA);
H.R.830, HELP Copays Act; S.127, Pharmacy Benefit Manager Transparency Act of 2023; H.R.3285, Fairness for Patient Medications Act; S.1339, Pharmacy Benefit Manager Reform Act;
Educational discussions around Vaccine Injury Compensation Program.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to related to appropriations, federal health programs, and prescription drugs; FY2024 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations; H.R.3746, Fiscal Responsibility Act of 2023; H.R.2811, Limit, Save, Grow Act of 2023.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; Drug Pricing;
H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169) implementation;
CMMI Proposed Accelerated Approval Payment Policy.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Biopharmaceutical innovation and patent policy issues.
Trademark legislative proposals.
Bayh-Dole march-in rights policy issues.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to pharmaceutical IP and supply chain.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Tax issues related to implementation of H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169).
Issues related to R&D tax credit; H.R.3938, Build It in America Act.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2023
In Q1, Crossroads Strategies, LLC lobbied for Sanofi US Services Inc. , earning $50,000. The report was filed on April 19, 2023.
Original Filing: 301457508.xml
Lobbying Issues
Issues related to health care, the Food and Drug Administration (FDA), Rx-to-OTC switch issues, influenza, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, TRICARE Pharmacy Program, VICP Program, and insulin price cap;
H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169) implementation;
H.R.830, HELP Copays Act;
S.127, Pharmacy Benefit Manager Transparency Act of 2023;
Pandemic and All-Hazards Preparedness Reauthorization Act (PAHPRA).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to related to appropriations, federal health programs, and prescription drugs; FY2024 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; Drug Pricing;
H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169) implementation;
CMMI Proposed Accelerated Approval Payment Policy.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Biopharmaceutical innovation and patent policy issues.
Trademark legislative proposals.
Bayh-Dole march-in rights policy issues.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to pharmaceutical IP and supply chain.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Tax issues related to implementation of H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169).
Issues related to R&D tax credit.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2022
In Q4, Crossroads Strategies, LLC lobbied for Sanofi US Services Inc. , earning $50,000. The report was filed on Jan. 19, 2023.
Original Filing: 301435369.xml
Lobbying Issues
Issues related to Rx-to-OTC switch issues, influenza, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, TRICARE Pharmacy Program, and PDUFA Reauthorization; S.920, The Affordable and Safe Prescription Drug Importation Act; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022; Improving Needed Safeguards for Users of Lifesaving Insulin Now (INSULIN) Act (draft legislation); VICP issues, FY2023 Consolidated Appropriations Act (H.R.2617).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to related to appropriations, federal health programs and prescription drugs; H.R.748, CARES Act (P.L.116-136) implementation; H.R.1319, American Rescue Plan Act of 2021 (P.L.117-2) implementation; FY2023 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act (H.R.8295, S.4659); VICP issues, FY2023 Consolidated Appropriations Act (H.R.2617).
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; Proposed Part B IPI Demonstration Project; Drug Pricing; H.R.1319, American Rescue Plan Act of 2021 (P.L.117-2) implementation; S.2428, False Claims Amendments Act of 2021; H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169) implementation.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Biopharmaceutical innovation and patent policy issues.
Trademark legislative proposals.
Bayh-Dole march-in rights policy issues.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to pharmaceutical IP and supply chain.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Tax issues related to implementation of H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169).
Issues related to R&D tax credit; FY2023 Consolidated Appropriations Act (H.R.2617).
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2022
In Q3, Crossroads Strategies, LLC lobbied for Sanofi US Services Inc. , earning $50,000. The report was filed on Oct. 20, 2022.
Original Filing: 301413337.xml
Lobbying Issues
Issues related to Rx-to-OTC switch issues, influenza, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, TRICARE Pharmacy Program, education around COVID-19 therapies, and PDUFA Reauthorization.
S.909, The Prescription Drug Price Relief Act; S.908, The Medicare Drug Price Negotiation Act; S.920, The Affordable and Safe Prescription Drug Importation Act; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022.
Improving Needed Safeguards for Users of Lifesaving Insulin Now (INSULIN) Act (draft legislation).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to related to appropriations, federal health programs and prescription drugs; H.R.748, CARES Act (P.L.116-136) implementation; H.R.1319, American Rescue Plan Act of 2021 (P.L.117-2) implementation; FY2023 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act (H.R.8295, S.4659).
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; Proposed Part B IPI Demonstration Project; Drug Pricing; Medicaid rebates and AMP Cap; H.R.1319, American Rescue Plan Act of 2021 (P.L.117-2) implementation; H.R.1868, To prevent across-the-board direct spending cuts, and for other purposes; H.R.3, Elijah E. Cummings Lower Drug Costs Now Act; S.2428, False Claims Amendments Act of 2021; FY2022 Budget Reconciliation (H.R.5376).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Biopharmaceutical innovation and patent policy issues.
Trademark legislative proposals.
Bayh-Dole march-in rights policy issues.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to pharmaceutical IP and supply chain; S.1260, United States Innovation and Competition Act of 2021; H.R.4521, America COMPETES Act of 2022.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Tax issues related to the Budget Reconciliation Process (H.R.5376).
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2022
In Q2, Crossroads Strategies, LLC lobbied for Sanofi US Services Inc. , earning $50,000. The report was filed on July 20, 2022.
Original Filing: 301390222.xml
Lobbying Issues
Issues related to Rx-to-OTC switch issues, influenza, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, TRICARE Pharmacy Program, education around COVID-19 therapies, and PDUFA Reauthorization.
S.909, The Prescription Drug Price Relief Act; S.908, The Medicare Drug Price Negotiation Act; S.920, The Affordable and Safe Prescription Drug Importation Act; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022.
Improving Needed Safeguards for Users of Lifesaving Insulin Now (INSULIN) Act (draft legislation).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to related to appropriations, federal health programs and prescription drugs; H.R.748, CARES Act (P.L.116-136) implementation; H.R.1319, American Rescue Plan Act of 2021 (P.L.117-2) implementation; FY2023 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; Proposed Part B IPI Demonstration Project; Drug Pricing; Medicaid rebates and AMP Cap; H.R.1319, American Rescue Plan Act of 2021 (P.L.117-2) implementation; H.R.1868, To prevent across-the-board direct spending cuts, and for other purposes; H.R.3, Elijah E. Cummings Lower Drug Costs Now Act; S.2428, False Claims Amendments Act of 2021; FY2022 Budget Reconciliation (H.R.5376).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Biopharmaceutical innovation and patent policy issues.
Trademark legislative proposals.
Bayh-Dole march-in rights policy issues.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to pharmaceutical IP and supply chain; S.1260, United States Innovation and Competition Act of 2021; H.R.4521, America COMPETES Act of 2022.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Tax issues related to the Budget Reconciliation Process (H.R.5376).
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2022
In Q1, Crossroads Strategies, LLC lobbied for Sanofi US Services Inc. , earning $50,000. The report was filed on April 19, 2022.
Original Filing: 301361007.xml
Lobbying Issues
Issues related to Rx-to-OTC switch issues, influenza, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, TRICARE Pharmacy Program, education around COVID-19 therapies, and PDUFA Reauthorization.
S.909, The Prescription Drug Price Relief Act; S.908, The Medicare Drug Price Negotiation Act; S.920, The Affordable and Safe Prescription Drug Importation Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to related to appropriations, federal health programs and prescription drugs; H.R.748, CARES Act (P.L.116-136) implementation; H.R.1319, American Rescue Plan Act of 2021 (P.L.117-2) implementation; FY2022 Consolidated Appropriations Act (H.R.2471, P.L.117-103); FY2023 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; Proposed Part B IPI Demonstration Project; Drug Pricing; Medicaid rebates and AMP Cap; H.R.1319, American Rescue Plan Act of 2021 (P.L.117-2) implementation; H.R.1868, To prevent across-the-board direct spending cuts, and for other purposes; H.R.3, Elijah E. Cummings Lower Drug Costs Now Act; S.2428, False Claims Amendments Act of 2021; FY2022 Budget Reconciliation (H.R.5376).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Biopharmaceutical innovation and patent policy issues.
Trademark legislative proposals.
Bayh-Dole march-in rights policy issues.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to pharmaceutical IP and supply chain; S.1260, United States Innovation and Competition Act of 2021; H.R.4521, America COMPETES Act of 2022.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Tax issues related to the Budget Reconciliation Process (H.R.5376).
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2021
In Q4, Crossroads Strategies, LLC lobbied for Sanofi US Services Inc. , earning $50,000. The report was filed on Jan. 19, 2022.
Original Filing: 301327942.xml
Lobbying Issues
Issues related to Rx-to-OTC switch issues, influenza, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, TRICARE Pharmacy Program, and education around COVID-19 therapies.
S.909, The Prescription Drug Price Relief Act; S.908, The Medicare Drug Price Negotiation Act; S.920, The Affordable and Safe Prescription Drug Importation Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to related to appropriations, federal health programs and prescription drugs;
FY2022 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act (H.R.4502, S.3062); H.R.748, CARES Act (P.L.116-136) implementation; H.R.133, Consolidated Appropriations Act, 2021 (P.L.116-260) implementation; H.R.1319, American Rescue Plan Act of 2021 (P.L.117-2) implementation; FY2022 Consolidated Appropriations Act (H.R.4502).
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; Proposed Part B IPI Demonstration Project; Drug Pricing; Medicaid rebates and AMP Cap;
H.R.1319, American Rescue Plan Act of 2021 (P.L.117-2) implementation; H.R.1868, To prevent across-the-board direct spending cuts, and for other purposes; H.R.3, Elijah E. Cummings Lower Drug Costs Now Act; FY2022 Budget Resolution (S.Con.Res.14)/Budget Reconciliation (H.R.5376); S.2428, False Claims Amendments Act of 2021.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Biopharmaceutical innovation and patent policy issues.
Trademark legislative proposals.
Bayh-Dole march-in rights policy issues.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to pharmaceutical IP and supply chain; S.1260, United States Innovation and Competition Act of 2021.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Tax issues related to the Budget Reconciliation Process (S.Con.Res.14, H.R.5376).
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2021
In Q3, Crossroads Strategies, LLC lobbied for Sanofi US Services Inc. , earning $50,000. The report was filed on Oct. 19, 2021.
Original Filing: 301306788.xml
Lobbying Issues
Issues related to Rx-to-OTC switch issues, influenza, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, TRICARE Pharmacy Program, and education around COVID-19 therapies.
S.909, The Prescription Drug Price Relief Act; S.908, The Medicare Drug Price Negotiation Act; S.920, The Affordable and Safe Prescription Drug Importation Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to related to appropriations, federal health programs and prescription drugs;
FY2022 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act (H.R.4502); H.R.748, CARES Act (P.L.116-136) implementation; H.R.133, Consolidated Appropriations Act, 2021 (P.L.116-260) implementation; H.R.1319, American Rescue Plan Act of 2021 (P.L.117-2) implementation; FY2022 Consolidated Appropriations Act (H.R.4502).
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; Proposed Part B IPI Demonstration Project; Drug Pricing; Medicaid rebates and AMP Cap;
H.R.1319, American Rescue Plan Act of 2021 (P.L.117-2) implementation; H.R.1868, To prevent across-the-board direct spending cuts, and for other purposes; H.R.3, Elijah E. Cummings Lower Drug Costs Now Act; FY2022 Budget Resolution (S.Con.Res.14)/Budget Reconciliation (H.R.5376); S.2428, False Claims Amendments Act of 2021.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Biopharmaceutical innovation and patent policy issues.
Trademark legislative proposals.
Bayh-Dole march-in rights policy issues.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to pharmaceutical IP and supply chain; S.1260, United States Innovation and Competition Act of 2021.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Tax issues related to the Budget Reconciliation Process (S.Con.Res.14, H.R.5376).
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2021
In Q2, Crossroads Strategies, LLC lobbied for Sanofi US Services Inc. , earning $50,000. The report was filed on July 18, 2021.
Original Filing: 301279208.xml
Lobbying Issues
Issues related to Rx-to-OTC switch issues, influenza, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, TRICARE Pharmacy Program, and education around COVID-19 therapies.
S.909, The Prescription Drug Price Relief Act; S.908, The Medicare Drug Price Negotiation Act; S.920, The Affordable and Safe Prescription Drug Importation Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to related to appropriations, federal health programs and prescription drugs;
FY2022 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act; H.R.748, CARES Act (P.L.116-136) implementation; H.R.133, Consolidated Appropriations Act, 2021 (P.L.116-260) implementation; H.R.1319, American Rescue Plan Act of 2021 (P.L.117-2).
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; Proposed Part B IPI Demonstration Project; Drug Pricing; Medicaid rebates and AMP Cap;
H.R.1319, American Rescue Plan Act of 2021 (P.L.117-2); H.R.1868, To prevent across-the-board direct spending cuts, and for other purposes; H.R.3, Elijah E. Cummings Lower Drug Costs Now Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Biopharmaceutical innovation and patent policy issues.
Trademark legislative proposals.
Bayh-Dole march-in rights policy issues.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to pharmaceutical IP and supply chain; S.1260, United States Innovation and Competition Act of 2021.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
1st Quarter, 2021
In Q1, Crossroads Strategies, LLC lobbied for Sanofi US Services Inc. , earning $50,000. The report was filed on April 19, 2021.
Original Filing: 301256423.xml
Lobbying Issues
Issues related to Rx-to-OTC switch issues, influenza, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, TRICARE Pharmacy Program, and education around COVID-19 therapies.
Executive Order on Access to Affordable Life-saving Medications (E.O.13937); Executive Order on Increasing Drug Importation to Lower Prices for American Patients (E.O.13938); Executive Order on Lowering Prices for Patients by Eliminating Kickbacks to Middlemen (E.O.13939); Executive Orders on Lowering Drug Prices by Putting America First (E.O.13947, E.O.13948); Executive Order on Combating Public Health Emergencies and Strengthening National Security by Ensuring Essential Medicines, Medical Countermeasures, and Critical Inputs Are Made in the United States (E.O.13944); Executive Order on An America-First Healthcare Plan (E.O.13951).
S.909, The Prescription Drug Price Relief Act; S.908, The Medicare Drug Price Negotiation Act; S.920, The Affordable and Safe Prescription Drug Importation Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to related to appropriations, federal health programs and prescription drugs;
FY2022 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act; H.R.748, CARES Act (P.L.116-136) implementation; H.R.133, Consolidated Appropriations Act, 2021 (P.L.116-260) implementation; H.R.1319, American Rescue Plan Act of 2021 (P.L.117-2).
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; Proposed Part B IPI Demonstration Project; Drug Pricing; Medicaid rebates and AMP Cap;
H.R.1319, American Rescue Plan Act of 2021 (P.L.117-2); H.R.1868, To prevent across-the-board direct spending cuts, and for other purposes.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Biopharmaceutical innovation and patent policy issues.
Trademark legislative proposals.
Bayh-Dole march-in rights policy issues.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to pharmaceutical IP and supply chain.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
4th Quarter, 2020
In Q4, Crossroads Strategies, LLC lobbied for Sanofi US Services Inc. , earning $50,000. The report was filed on Jan. 20, 2021.
Original Filing: 301241177.xml
Lobbying Issues
Issues related to Over the Counter (OTC) Monograph reform, influenza, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, TRICARE Pharmacy Program, education around COVID-19 therapies, and COVID-19 liability protection legislative proposals.
Implementation of Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019 (P.L.116-22).
Executive Order on Access to Affordable Life-saving Medications (E.O. 13937).
Executive Order on Increasing Drug Importation to Lower Prices for American Patients (E.O. 13938).
Executive Order on Lowering Prices for Patients by Eliminating Kickbacks to Middlemen (E.O. 13939).
Executive Orders on Lowering Drug Prices by Putting America First (E.O. 13947, E.O. 13948).
Executive Order on Combating Public Health Emergencies and Strengthening National Security by Ensuring Essential Medicines, Medical Countermeasures, and Critical Inputs Are Made in the United States (E.O. 13944).
Executive Order on An America-First Healthcare Plan (E.O. 13951).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to related to appropriations, federal health programs and prescription drugs;
H.R.6395/S.4049, National Defense Authorization Act for Fiscal Year 2021;
FY2021 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act (H.R.7614), FY2021 Consolidated Appropriations Act (H.R.7617);
H.R.6074, Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 (P.L. 116-123); H.R.266, Paycheck Protection Program and Health Care Enhancement Act (P.L.116-139); H.R.748, CARES Act (P.L.116-136); H.R.6800, The Heroes Act; The HEALS Act; H.R.8337, Continuing Appropriations Act, 2021 and Other Extensions Act; H.R.133, Making consolidated appropriations for the fiscal year ending September 30, 2021, providing coronavirus emergency response and relief, and for other purposes (P.L.116-260).
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid, such as: Part D Medicare Program, Medicare Part B reimbursement, and drug pricing.
Proposed Part B IPI Demonstration Project.
H.R.3, Lower Drug Costs Now Act of 2019; S.2543, Prescription Drug Pricing Reduction Act of 2019; H.R.19, Lower Costs, More Cures Act of 2019; S.1895, Lower Health Care Costs Act of 2019; H.R.1425, Patient Protection and Affordable Care Enhancement Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Biopharmaceutical innovation and patent policy issues.
Trademark legislative proposals.
Bayh-Dole march-in rights policy issues.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to prescription drug supply chains; H.R.6482/S.3537/S.3635, Protecting Our Pharmaceutical Supply Chain from China Act of 2020; H.R.6431, Made in America Emergency Preparedness Act.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
3rd Quarter, 2020
In Q3, Crossroads Strategies, LLC lobbied for Sanofi US Services Inc. , earning $50,000. The report was filed on Oct. 18, 2020.
Original Filing: 301212709.xml
Lobbying Issues
Issues related to Over the Counter (OTC) Monograph reform, influenza, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, TRICARE Pharmacy Program, education around COVID-19 therapies, and COVID-19 liability protection legislative proposals.
Implementation of Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019 (P.L.116-22).
Executive Order on Access to Affordable Life-saving Medications (E.O. 13937).
Executive Order on Increasing Drug Importation to Lower Prices for American Patients (E.O. 13938).
Executive Order on Lowering Prices for Patients by Eliminating Kickbacks to Middlemen (E.O. 13939).
Executive Orders on Lowering Drug Prices by Putting America First (E.O. 13947, E.O. 13948).
Executive Order on Combating Public Health Emergencies and Strengthening National Security by Ensuring Essential Medicines, Medical Countermeasures, and Critical Inputs Are Made in the United States (E.O. 13944).
Executive Order on An America-First Healthcare Plan (E.O. 13951).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to related to appropriations, federal health programs and prescription drugs;
H.R.6395/S.4049, National Defense Authorization Act for Fiscal Year 2021;
FY2021 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act (H.R.7614), FY2021 Consolidated Appropriations Act (H.R.7617);
H.R.6074, Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 (P.L. 116-123); H.R.266, Paycheck Protection Program and Health Care Enhancement Act (P.L.116-139); H.R.748, CARES Act (P.L.116-136); H.R.6800, The Heroes Act; The HEALS Act; H.R.8337, Continuing Appropriations Act, 2021 and Other Extensions Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid, such as: Part D Medicare Program, Medicare Part B reimbursement, and drug pricing.
Proposed Part B IPI Demonstration Project.
H.R.3, Lower Drug Costs Now Act of 2019.
S.2543, Prescription Drug Pricing Reduction Act of 2019.
H.R.19, Lower Costs, More Cures Act of 2019.
S.1895, Lower Health Care Costs Act of 2019.
H.R.1425, Patient Protection and Affordable Care Enhancement Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Biopharmaceutical innovation and patent policy issues.
Trademark legislative proposals.
Bayh-Dole march-in rights policy issues.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to prescription drug supply chains; H.R.6482/S.3537/S.3635, Protecting Our Pharmaceutical Supply Chain from China Act of 2020; H.R.6431, Made in America Emergency Preparedness Act.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
2nd Quarter, 2020
In Q2, Crossroads Strategies, LLC lobbied for Sanofi US Services Inc. , earning $50,000. The report was filed on July 19, 2020.
Original Filing: 301193745.xml
Lobbying Issues
Issues related to Over the Counter (OTC) Monograph reform, influenza, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, TRICARE Pharmacy Program, and education around COVID-19 therapies.
Implementation of Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019 (P.L.116-22).
S.1895, Lower Health Care Costs Act of 2019.
H.R.6395/S.4049, National Defense Authorization Act for Fiscal Year 2021.
H.R.6482/S.3537/S.3635, Protecting Our Pharmaceutical Supply Chain from China Act of 2020.
H.R.6431, Made in America Emergency Preparedness Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
FY 2021 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations.
H.R.6074, Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 (P.L. 116-123).
H.R.266, Paycheck Protection Program and Health Care Enhancement Act (P.L.116-139).
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid, such as: Part D Medicare Program, Medicare Part B reimbursement, and drug pricing.
Proposed Part B IPI Demonstration Project.
S.551, REFUND Act of 2019.
H.R.3, Lower Drug Costs Now Act of 2019.
S.2543, Prescription Drug Pricing Reduction Act of 2019.
H.R.19, Lower Costs, More Cures Act of 2019.
H.R.748, CARES Act (P.L.116-136) implementation.
H.R.6800, The Heroes Act.
H.R.1425, State Health Care Premium Reduction Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to pharmaceutical patents; S.1416, Affordable Prescriptions for Patients Act of 2019.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
1st Quarter, 2020
In Q1, Crossroads Strategies, LLC lobbied for Sanofi US Services Inc. , earning $50,000. The report was filed on April 19, 2020.
Original Filing: 301172269.xml
Lobbying Issues
Issues related to Over the Counter (OTC) Monograph reform, influenza, 340B Program, drug pricing, importation of biopharmaceuticals, and the international pharmaceutical supply chain.
Implementation of Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019 (P.L.116-22).
S.1895, Lower Health Care Costs Act of 2019.
Education around COVID-19 therapies.
Agencies Lobbied
U.S. Senate
Lobbying Issues
FY 2021 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations.
H.R.6074, Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 (P.L. 116-123).
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid, such as: Part D Medicare Program, Medicare Part B reimbursement, and drug pricing.
Proposed Part B IPI Demonstration Project.
S.551, REFUND Act of 2019.
H.R.3, Lower Drug Costs Now Act of 2019.
S.2543, Prescription Drug Pricing Reduction Act of 2019.
H.R.19, Lower Costs, More Cures Act of 2019.
H.R.748, CARES Act (P.L.116-136).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to pharmaceutical patents; S.1416, Affordable Prescriptions for Patients Act of 2019.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
4th Quarter, 2019
In Q4, Crossroads Strategies, LLC lobbied for Sanofi US Services Inc. , earning $50,000. The report was filed on Jan. 19, 2020.
Original Filing: 301121766.xml
Lobbying Issues
Issues related to Over the Counter (OTC) Monograph reform, influenza, 340B Program, drug pricing, and the importation of biopharmaceuticals.
Implementation of Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019 (P.L.116-22).
S.1895, Lower Health Care Costs Act of 2019.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R.3164/S.2522, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2020 and H.R.3055, the FY2020 Consolidated measure;
H.R.2740, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2020, H.R.2968, Department of Defense Appropriations Act, 2020, and H.R.2740, the FY2020 Consolidated measure;
H.R.1158, Consolidated Appropriations Act, 2020 (P.L.116-93);
H.R.1865, Further Consolidated Appropriations Act, 2020 (P.L.116-94).
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid, such as: Part D Medicare Program, Medicare Part B reimbursement, and drug pricing.
Proposed Part B IPI Demonstration Project.
S.551, REFUND Act of 2019.
H.R.3, Lower Drug Costs Now Act of 2019.
S.2543, Prescription Drug Pricing Reduction Act of 2019.
H.R.19, Lower Costs, More Cures Act of 2019.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to pharmaceutical patents; S.1416, Affordable Prescriptions for Patients Act of 2019.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
3rd Quarter, 2019
In Q3, Crossroads Strategies, LLC lobbied for Sanofi US Services Inc. , earning $50,000. The report was filed on Oct. 19, 2019.
Original Filing: 301072176.xml
Lobbying Issues
Issues related to Over the Counter (OTC) Monograph reform, influenza, 340B Program, drug pricing, and the importation of biopharmaceuticals.
Implementation of Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019 (P.L.116-22).
S.1895, Lower Health Care Costs Act of 2019.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R.3164/S.2522, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2020 and H.R.3055, the FY2020 Consolidated measure.
H.R.2740, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2020, H.R.2968, Department of Defense Appropriations Act, 2020, and H.R.2740, the FY2020 Consolidated measure.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid, such as: Part D Medicare Program and Medicare Part B reimbursement.
Proposed Part B IPI Demonstration Project.
Proposed HHS Rule on Rebates.
S.551, REFUND Act of 2019.
H.R.3, Lower Drug Costs Now Act of 2019.
S.2543, Prescription Drug Pricing Reduction Act of 2019.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to pharmaceutical patents; S.1416, Affordable Prescriptions for Patients Act of 2019.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
2nd Quarter, 2019
In Q2, Crossroads Strategies, LLC lobbied for Sanofi US Services Inc. , earning $50,000. The report was filed on July 20, 2019.
Original Filing: 301053285.xml
Lobbying Issues
Issues related to Over the Counter (OTC) Monograph reform, influenza, 340B Program, drug pricing, and the importation of biopharmaceuticals.
H.R.269/S.1379, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019 (P.L.116-22), including provisions related to the Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2019.
S.1895, Lower Health Care Costs Act of 2019.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R.3164, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2020 and H.R.3055, the FY2020 Consolidated measure.
H.R.2740, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2020, H.R.2968, Department of Defense Appropriations Act, 2020, and H.R.2740, the FY2020 Consolidated measure.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid, such as: Part D Medicare Program and Medicare Part B reimbursement.
Proposed Part B IPI Demonstration Project.
Proposed HHS Rule on Rebates.
S.551, REFUND Act of 2019.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to pharmaceutical patents; S.1416, Affordable Prescriptions for Patients Act of 2019.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
1st Quarter, 2019
In Q1, Crossroads Strategies, LLC lobbied for Sanofi US Services Inc. , earning $50,000. The report was filed on April 22, 2019.
Original Filing: 301033169.xml
Lobbying Issues
Issues related to Over the Counter (OTC) Monograph reform, influenza, and drug pricing;
H.R.269, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019 including provisions related to the Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2019.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.J.Res.31, Consolidated Appropriations Act, 2019 (P.L.116-6);
FY 2020 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations;
FY 2020 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations;
FY 2020 Department of Defense Appropriations.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid, such as: Part D Medicare Program (including Coverage Gap and other offsets) and Medicare Part B reimbursement.
Proposed Part B IPI Demonstration Project.
Proposed HHS Rule on Rebates.
S.551, REFUND Act of 2019.
Agencies Lobbied
U.S. Senate
4th Quarter, 2018
In Q4, Crossroads Strategies, LLC lobbied for Sanofi US Services Inc. , earning $40,000. The report was filed on Jan. 20, 2019.
Original Filing: 301011029.xml
Lobbying Issues
Issues related to Over the Counter (OTC) Monograph reform, influenza, and drug pricing;
S.2852/H.R.6378, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018;
S.2434/H.R.5554, Animal Drug and Animal Generic Drug User Fee Amendments of 2018 (P.L.115-234);
S.2315, Over-the-Counter Drug Safety, Innovation, and Reform Act;
H.R.5333, Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2018.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R.5961/S.2976, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2019;
H.R.5895, Energy and Water, Legislative Branch, and Military Construction and Veterans Affairs Appropriations Act, 2019 (P.L.115-244);
H.R.6157, Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019 (P.L.115-245).
Agencies Lobbied
U.S. Senate
Lobbying Issues
General issues related to Medicare and Medicaid, such as: Part D Medicare Program (including Coverage Gap and other offsets) and Medicare Part B reimbursement.
Proposed Part B IPI Demonstration Project.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2018
In Q3, Crossroads Strategies, LLC lobbied for Sanofi US Services Inc. , earning $40,000. The report was filed on Oct. 19, 2018.
Original Filing: 300993115.xml
Lobbying Issues
Issues related to Over the Counter (OTC) Monograph reform, influenza, and drug pricing;
S.2852, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018; H.R.6378, To reauthorize certain programs under the Pandemic and All-Hazards Preparedness Reauthorization Act;
S.2434/H.R.5554, Animal Drug and Animal Generic Drug User Fee Amendments of 2018 (P.L.115-234);
S.2315, Over-the-Counter Drug Safety, Innovation, and Reform Act; H.R.5333, Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2018.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R.5786/S.3024, Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2019;
S.3158/H.R.6470, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2019;
H.R.5961/S.2976, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2019;
H.R.5895, Energy and Water, Legislative Branch, and Military Construction and Veterans Affairs Appropriations Act, 2019 (P.L.115-244);
H.R.6147, Interior, Environment, Financial Services and General Government, Agriculture, Rural Development, Food and Drug Administration, and Transportation, Housing and Urban Development Appropriations Act, 2019;
H.R.6157, Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019 (P.L.115-245).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Part D Medicare Program (including Coverage Gap and other offsets).
Medicare Part B reimbursement.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2018
In Q2, Crossroads Strategies, LLC lobbied for Sanofi US Services Inc. , earning $40,000. The report was filed on July 20, 2018.
Original Filing: 300973501.xml
Lobbying Issues
Issues related to Over the Counter (OTC) Monograph reform, influenza, and drug pricing;
S.2852, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018;
S.2434, Animal Drug and Animal Generic Drug User Fee Amendments of 2018.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R.5786/S.3024, Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2019;
S.3158/House Draft, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2019;
H.R.5961/S.2976, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2019.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Part D Medicare Program (including Coverage Gap and other offsets).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation of H.R.1, Tax Cuts and Jobs Act (P.L.115-97).
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2018
In Q1, Crossroads Strategies, LLC lobbied for Sanofi US Services Inc. , earning $30,000. The report was filed on April 20, 2018.
Original Filing: 300953913.xml
Lobbying Issues
Issues related to Over the Counter (OTC) Monograph reform, influenza, drug pricing, and the Pandemic and All-Hazards Preparedness Act (PAHPA), P.L.109-417.
Agencies Lobbied
U.S. Senate
Lobbying Issues
FY19 Military Construction, Veterans Affairs, and Related Agencies Appropriations; FY19 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations; FY19 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Part D Medicare Program (including Coverage Gap and other offsets in H.R.1892/P.L.115-123, Bipartisan Budget Act of 2018).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation of H.R.1, Tax Cuts and Jobs Act (P.L.115-97).
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2018
Crossroads Strategies, LLC filed a lobbying registration on March 9, 2018 to represent Sanofi US Services Inc., effective Feb. 1, 2018.
Original Filing: 300941330.xml
Issue(s) they said they’d lobby about: Pandemic health issues; influenza issues; OTC monograph reform; Part D Medicare program; drug pricing; implementation of H.R.1, Tax Cuts and Jobs Act (P.L.115-97). .
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate
Searching...